| 查看: 295 | 回复: 2 | |||
[交流]
帮忙翻译两段摘要(中to英文)
|
|
摘要 目的:分析我院止吐药用药金额、用药构成比以及DDDs排序,了解我院止 吐药用药现状,为临床治疗提供参考。方法:对我院2009-2010年止吐药用药金额 、用药构成比以及DDDs排序进行比较分析。结果:我院两年来化疗止吐药的销售 金额呈上升趋势,两年用药构成比以及DDDs排序无明显变化,用药以 5-羟色胺受 体拮抗剂为主。结论:我院止吐药5-羟色胺受体拮抗剂用量增长稳定,在我院占主 导地位,止吐药用药基本合理。 关键词 止吐药;用药金额;用药构成比;DDDs排序;用药现状 摘要 目的:分析免疫增强剂用药金额、用药构成比以及DDDs排序,了解用药现状,为临床治疗提供参考。方法:对我院住院药房2009-2010年免疫增强剂用药金额、用药构成比以及DDDs排序进行统计比较分析。结果:我院免疫增强剂的用药金额呈上升趋势,从用药构成比及DDDs排序来看,胸腺肽制剂占第一位,两年的DDDs排序无明显变化。结论:我院免疫增强剂金额增长稳定,胸腺肽制剂占第一位,是免疫增强剂用药主体,免疫增强剂用药基本合理。 关键词 免疫增强剂;用药金额;用药构成比;DDDs排序;用药现状 |
» 猜你喜欢
售SCI一区文章,我:8O5.5.1.O5.4,科目全,可伽急
已经有3人回复
售SCI一区文章,我:8.O.551.O.5.4,科目全,可伽急
已经有3人回复
售SCI一区T0P文章,我:8O.55.1.O.5.4,科目齐全,可+急
已经有3人回复
售SCI文章,我:8O5.5.1.O.54,科目齐全,可+急
已经有3人回复
售SCI一区文章,我:8.O.551.O.5.4,科目全,可伽急
已经有3人回复
售SCI文章,我:8O5.5.1.O.54,科目齐全,可+急
已经有3人回复
售SCI-T0P文章,我:8O.5.5.1.O.54,科目齐全,可+急
已经有6人回复
售一区SCI文章T0P,我:8O.551.O54,科目全,可十急
已经有9人回复
售SCI-T0P文章,我:8O.5.5.1.O.54,科目齐全,可+急
已经有3人回复
考博求助
已经有3人回复
★ ★ ★ ★ ★
ringzhu(金币+5): 辛苦了~~欢迎常来本版 2011-04-02 10:45:24
ringzhu(金币+5): 辛苦了~~欢迎常来本版 2011-04-02 10:45:24
|
Abstract The aim of this study is to analyze the amount and the constituent ratio of the medication and the sequence of DDDs of sort antiemetic medication in our hospital. We provide a reference for clinical treatment based on the current station of the antiemetic medication. We compared and analysis the amount and the ratio of medication and the sequence of DDDs between 2009 and 2010. The results showed that the amount of chemotherapy antiemetic sales increased, and there were no significant changes in the constituent of medication and the sequence of DDDs within two years. The medicine was mainly based 5 - hydroxytryptamine receptor antagonists. Above all, we can get to the conclusion that the amount of antiemetic 5 - hydroxytryptamine receptor antagonists increased stable and have a dominant station in our hospital. The results proved the reasonable of antiemetic medication. Keywords antiemetic; drug amount; drug constituent ratio; DDDs sort; drug status |
2楼2011-04-01 22:48:02
3楼2011-04-01 22:48:47










回复此楼